Connection

Philip Hall to Humans

This is a "connection" page, showing publications Philip Hall has written about Humans.
Connection Strength

0.179
  1. The Report of the 2018-2019 Professional Affairs Standing Committee: The Role of Educators in Pharmacy Practice Transformation. Am J Pharm Educ. 2019 12; 83(10):7596.
    View in: PubMed
    Score: 0.026
  2. Experience with dasatinib and nilotinib use in pregnancy. J Oncol Pharm Pract. 2018 Mar; 24(2):121-128.
    View in: PubMed
    Score: 0.021
  3. A continuous quality improvement program to focus a college of pharmacy on programmatic advancement. Am J Pharm Educ. 2013 Aug 12; 77(6):117.
    View in: PubMed
    Score: 0.017
  4. Toxicities of gemcitabine in patients with severe hepatic dysfunction. Ann Pharmacother. 2010 Apr; 44(4):750-4.
    View in: PubMed
    Score: 0.013
  5. Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein. Anticancer Drugs. 2008 Nov; 19(10):1007-11.
    View in: PubMed
    Score: 0.012
  6. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy. 2006 Jun; 26(6):806-12.
    View in: PubMed
    Score: 0.010
  7. Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy. Cancer Immunol Immunother. 2006 Aug; 55(8):928-32.
    View in: PubMed
    Score: 0.010
  8. Treatment of acute myeloid leukemia during the second and third trimesters of pregnancy. Pharmacotherapy. 2005 Aug; 25(8):1134-40.
    View in: PubMed
    Score: 0.010
  9. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clin Immunol. 2001 Aug; 100(2):191-7.
    View in: PubMed
    Score: 0.007
  10. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. Leukemia. 1999 Apr; 13(4):629-33.
    View in: PubMed
    Score: 0.006
  11. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice. Toxicol Appl Pharmacol. 1998 May; 150(1):91-7.
    View in: PubMed
    Score: 0.006
  12. A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Cancer. 1997 Mar 01; 79(5):1037-43.
    View in: PubMed
    Score: 0.005
  13. The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol. 1995 Nov; 23(12):1256-60.
    View in: PubMed
    Score: 0.005
  14. Adjuvant therapy of node-negative breast cancer. Ann Pharmacother. 1995 Mar; 29(3):289-98.
    View in: PubMed
    Score: 0.005
  15. Immunomodulation with intravenous immunoglobulin. Pharmacotherapy. 1993 Nov-Dec; 13(6):564-73.
    View in: PubMed
    Score: 0.004
  16. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer. 2010 Feb; 19(2):231-7.
    View in: PubMed
    Score: 0.003
  17. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res. 2005 Jan 01; 11(1):329-34.
    View in: PubMed
    Score: 0.002
  18. Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. Leuk Lymphoma. 2004 Aug; 45(8):1647-56.
    View in: PubMed
    Score: 0.002
  19. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif. 2004 Jan; 33(1):123-33.
    View in: PubMed
    Score: 0.002
  20. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3555-61.
    View in: PubMed
    Score: 0.002
  21. Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion. Pharmacotherapy. 2002 Sep; 22(9):1188-92.
    View in: PubMed
    Score: 0.002
  22. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res. 2002 May; 8(5):1004-13.
    View in: PubMed
    Score: 0.002
  23. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconjug Chem. 1998 Jul-Aug; 9(4):490-6.
    View in: PubMed
    Score: 0.001
  24. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. Blood. 1997 Nov 01; 90(9):3654-61.
    View in: PubMed
    Score: 0.001
  25. Synthesis of green fluorescent protein-ricin and monitoring of its intracellular trafficking. Bioconjug Chem. 1997 Sep-Oct; 8(5):743-50.
    View in: PubMed
    Score: 0.001
  26. Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells. Leuk Res. 1997 Jul; 21(7):681-90.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.